Abbott Structural Heart Device Registry

ASD - Atrial Septal Defect, Heart Diseases, PFO - Patent Foramen Ovale, PIVSD - Post Infarct Muscular Ventricular Septal Defect, Valvular Heart Disease, VSD - Muscular Ventricular Septal Defect

Amplatzer, Amplatzer Septal Occluder, Amplatzer Multi-fenestrated (Cribriform) Occluder, Amplatzer Duct Occluder, Amplatzer Piccolo Occluder, Amplatzer Muscular VSD Occluder, Amplatzer Post-Infarct VSD Occluder, Amplatzer Talisman, Amplatzer TorqVue Delivery System, Amplatzer Sizing Balloon, Amplatzer Guidewire, Amplatzer Occluder devices, Surgical Valves, Epic Plus Aortic Valve, Epic Plus Mitral Valve, Epic Plus Supra Aortic Valve, Epic Max Aortic Valve, Bioprosthetic heart valve, Surgical tissue heart valve, Amplatzer Piccolo Delivery System, Epic Elite Aortic Valve, Epic Elite Mitral Valve, Epic Supra G3 Aortic Valve

The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting. The Registry primarily involves gathering data from routine hospital practices and standard-of-care (SOC) procedures administered to patients. All devices used in these procedures must be commercially available to the participating site. A list of specific devices covered by the Registry are available upon request from the Sponsor. Data generated by the Registry will be used to meet regulatory requirements, such as the European Union Medical Device Regulations 2017/745, that require active post-market clinical follow-up (PMCF) for all commercially available devices.

The Abbott SH Device Registry is designed to confirm the safety and performance of commercially available Abbott SH devices as they are used in routine hospital practice or SOC procedures. Patients will be screened for eligibility and willingness to participate prior to the procedure or, if enrolled retrospectively, within the following timeframes: * Amplatzer portion: within 7 days post-procedure * Cardiac Surgery portion (The ENDURE Study): within 6 months post-procedure. All patients who provide informed consent and undergo an implant attempt with an applicable Abbott SH device are eligible to participate in the Registry. The Registry anticipates that approximately 500 subjects per year will be enrolled. The projected enrollment period is at least 5 years. The Registry will be conducted at approximately 25 sites worldwide. Additional sites may be approached for participation in the Registry as needed. Follow-up visits should align with the site's routine SOC visits for the associated procedure. Data collection will occur post-screening and consent and at post-procedure SOC follow-up visit(s). Where applicable, follow-up visits may occur over the telephone, virtually, or in-office, following SOC practice. The follow-up duration will depend on the Abbott device(s) used during the procedure. Certain devices will utilize data collection at discharge (or 7 days post procedure, whichever comes first), short-term (1 - 3 months as applicable), a mid-term (6 months), and long-term follow-up (12 months) visits to support clinical safety and performance data requirements. Alternatively, some devices will have follow-up visits extending up to 10 years to monitor subjects throughout the devices' lifetime. A surgical valve-specific "Line Extension Sub-Study" is included in the protocol to collect data at European sites with the intention of applying for approval in the US for 2 specific surgical aortic valve sizes (Epic Max 27mm, and the Epic Plus Supra 29mm).

No related papers found yet.

Denmark, Estonia, France, Germany, Ireland, Italy, Poland, Spain, United Kingdom, United States